A discovery and verification approach to pharmacovigilance using electronic healthcare data.

Introduction: Pharmacovigilance is vital for drug safety. The process typically involves two key steps: initial signal generation from spontaneous reporting systems (SRSs) and subsequent expert review to assess the signals' (potential) causality and decide on the appropriate action.

Methods: We propose a novel discovery and verification approach to pharmacovigilance based on electronic healthcare data.

Variable selection in linear regression models: Choosing the best subset is not always the best choice.

We consider the question of variable selection in linear regressions, in the sense of identifying the correct direct predictors (those variables that have nonzero coefficients given all candidate predictors). Best subset selection (BSS) is often considered the "gold standard," with its use being restricted only by its NP-hard nature. Alternatives such as the least absolute shrinkage and selection operator (Lasso) or the Elastic net (Enet) have become methods of choice in high-dimensional settings.

Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems.

Purpose: Spontaneous reporting systems (SRSs) are used to discover previously unknown relationships between drugs and adverse drug reactions (ADRs). A plethora of statistical methods have been proposed over the years to identify these drug-ADR pairs. The objective of this study is to compare a wide variety of methods in their ability to detect these signals, especially when their detection is complicated by the presence of innocent bystanders (drugs that are mistaken to be associated with the ADR, since they are prescribed together with the drug that is the ADR's actual cause).

[Detection of drug risks after approval : Methods development for the use of routine statutory health insurance data].

Adverse drug reactions are among the leading causes of death. Pharmacovigilance aims to monitor drugs after they have been released to the market in order to detect potential risks. Data sources commonly used to this end are spontaneous reports sent in by doctors or pharmaceutical companies.

A high-quality human reference panel reveals the complexity and distribution of genomic structural variants.

Structural variation (SV) represents a major source of differences between individual human genomes and has been linked to disease phenotypes. However, the majority of studies provide neither a global view of the full spectrum of these variants nor integrate them into reference panels of genetic variation. Here, we analyse whole genome sequencing data of 769 individuals from 250 Dutch families, and provide a haplotype-resolved map of 1.